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Computerized detection of morphological changes to
glioma cells during estramustine and ion-channel
blocker perifusion
P Behnam-Motlagh1'2, 0 Jonsson1'2, KG Engstrom3, R Henriksson2 and K Grankvist'
Departments of 'Clinical Chemistry, 2Oncology and 3Cardiothoracic Surgery, UmeA University, S-901 87 UmeS, Sweden
Summary A perifusion technique for microscopy with computerized detection of early changes in cell morphology during continuous
perifusion was used to show that the geometry of cultured glioma cells (MG-251) changes rapidly when they are exposed to estramustine
phosphate (EMP). When the cells were exposed to 20 or 40 mg 1-' EMP, cell volume projected cell area (PCA) rapidly increased. When the
Na+, K+-ATPase blocker ouabain (100 ,umol 1-') was added to the EMP (40 mg 1-') perifusion, the acute EMP response was eradicated. When
the PCA curve for ouabain alone was subtracted from the curve of combined ouabain and EMP perifusion, the resulting curve showed that
ouabain completely blocked the EMP-induced increase in PCA. When the Na+, K+, Cl- co-transport inhibitors bumetanide (10 lmol 1-'), or
furosemide (100 ,umol 1-'), were added to EMP (40 mg 1-'), the acute increase in PCA seen for EMP alone was also completely blocked. This
study shows that inhibitors of ion transmembrane transport can modify EMP-induced cell volume increases. This may be of particular
importance since the blockers have been found to interfere also with the cytotoxic function of EMP during cell culture. Thus, it is possible that
cell volume changes could serve as a rapid technique for predicting the cytotoxic activity of antineoplastic drugs.
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An intact cell volume is known to be ofcritical importance for the
preservation of cell functions, including growth and proliferation
(Hoffman and Simonsen, 1989). Extensive studies on cell volume
regulation in the last few years indicate that a wide variety ofcells
share common regulatory capacities, although a pronounced diver-
sity exists between different cell types in the nature of the ion
transport systems involved. It is well known that transmembrane
fluxes ofcations are part ofimportant cell functions, such as main-
tenance of the membrane potential regulation, intracellular pH
(DeWeer, 1985), and volume regulation in anisotonic media
(Hoffman and Simonsen, 1989). Predictive tumour sensitivity tests
have received increasing attention, and several different predictive
cellular and animal systems have been developed with varying
degree of success (Chapman et al, 1989). There is, thus, still a
strong need for more effective predictive tests of drug sensitivity
in clinical oncology.
Estramustine phosphate (EMP), a cytotoxic nor-nitrogen
mustard derivative of oestradiol 17p-phosphate, is generally
accepted in the treatment of advanced prostatic carcinoma
(Madajewics et al, 1980), and recently it has been shown to exert
considerable cytotoxic effects on several glioma cell lines (von
Schoultz et al, 1988; von Schoultz et al, 1990). In the present
study, we have investigated the effect of bumetanide and
furosemide, inhibitors of Na+, K+, Cl- co-transport, and ouabain,
an inhibitor of Na+, K+-ATPase, on the cytotoxic effect of EMP.
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This was done by means of a new microscopic technique that
provides the ability to follow early alterations in cell size and
shape ofcells perifused with anti cancer drugs. The use ofthe term
'perifusion' describes a situation in which a structure (a cell) is
surrounded by a medium flow. This technique was used in a
previous study from our laboratory (Engstrom et al, 1991) but is
here refined with fully digitized image processing for rapid
and precise measurements of cancer cell morphology, giving a
practical possibility to work as a predictive tool in cancer
chemotherapy. We show that acute changes in cell size correlate
strictly to the concentration of EMP in the perfusion systems.
However, the Na+, K+, Cl- co-transport and Na+, K+-ATPase
blockers are shown to have dramatic effects on cancer cell
morphology and seem to interact fully with the EMP response.
MATERIALS AND METHODS
Cell culture
The human malignant glioma cell line MG-251 was grown as
monolayer culture in Eagle's minimal essential medium (MEM)
supplemented with 10% fetal calfserum. The cells were incubated
at 37°C in humidified atmosphere containing 5% carbon dioxide.
Medium was changed three times a week. Cells were harvested by
incubation with 0.2 ml ofEDTA (5.0 mmol 1-') for 5 min followed
by trypsin (0.1%). The cells were portioned into plastic tissue
culture dishes containing basal medium and then kept under
controlled conditions (37°C and 5% carbon dioxide) before use.
Estramustine phosphate [oestradiol-3-N-bis (chloroethyl) carba-
mate phosphate] was diluted in Eagle's MEM to appropriate
concentrations and included in the incubation media.
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Figure 1 Schematic illustration showing the perifusion chamber and microscopic configuration. The chamber frame (1) is positioned on the microscope stage.
Cells are introduced into the perfusion space (2) and perifused with medium from the chamber medium reservoir (3) and by a peristaltic pump (4). A flow
vibration damper is connected in the fluid line (5). Input medium is from two external medium reservoirs (6, 7) to fill the chamber (3). The chamber medium
reservoir (3) can be emptied by a suction device (8). An extra input channel (9) to the perfusion space (2) can be used for cell injection and flushing. A heat
control system maintains a stable temperature (10) monitored by a temperature sensor (11)
Experimental set-up for cell microperifusion
The microperifusion device (Figure 1) consisted ofa plastic frame,
75 x 25 x 4.5 mm with a thin-bottom glass slide. At one end, and
at 250 gm distance from the bottom, there is a smaller glass slide
that gives rise to two compartments; one cell compartment for
perifusion (about 85 ,ul) and a larger medium reservoir (about
3.5 ml). The cell compartment is open towards the medium reser-
voir so that medium can enter during perifusion. Evaporation from
the reservoir was prevented by aglass-top cover. During a pause in
perifusion, the medium reservoir is drained from basal medium
and a drug-containing medium is added. When the pump is
restarted the test medium is aspirated into the cell compartment
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Table 1 Glioma cell geometry
Parameter Unit Mean sem n
Projected cell area tim2 189.9 ± 4.1 65
Circular diameter gm 16.1 ± 0.3 65
Spherical volume gm3 1400 ± 69 65
Shape factor 1 = circle 0.90 + 0.0045 65
Glioma cells were harvested and introduced into a perifusion chamber to
measure the geometry of individual cells by computerized image processing.
The geometric parameters in the table refer to the mean values of all tested
cells during the final 5 min basal medium perifusion. The PCA and perimeter
were measured by the computer to calculate the shape factor. In addition, the
PCA was also recalculated to yield the circular diameter and the volume of
an assumed spherical cell. n = number of cells analysed.
with a sharply defined interface between the two media. By
knowing the pump speed, the geometry of the cell compartment
and the location of the cell (about 8 mm from the compartment
entrance), the timing ofcell exposure can be predicted, here being
of the order of 10 s. Note, in this study, and for best experimental
reproducibility, this 10-s delay was incorporated into the first
minute ofperifusion and thus the 60-s recording represents 50 s of
true drug exposure. A peristaltic pump (LKB 12000 Varioperpex,
LKB, Bromma, Sweden) was used and connected in series with a
flow vibration damper to prevent vibrations from the pump
dislodging the cells in the chamber. The inverted phase-contrast
microscope, Zeiss Axiovert (with oil objective lens 100: 1.25), on
which stage the microperifusion device was mounted, was
equipped with a thermostated box and inlet media were preheated
before entering the chamber reservoir in which the temperature
was further stabilized before its entrance into the cell space.
Cells were recorded continuously on the computer screen and
with automatic intermittent computer inputs. The morphology of
individual cells was automatically measured by a computerized
image analyser IBAS 25 (Kontron Image Analysis Division, Zeiss,
Oberkochen, Germany). The computer was programmed for
automatic timing of the experimental phases, with one input per
minute, and separating basal and test medium perifusions. The
original images were stored on disc followed by a rerun after
the experiment, during which background subtraction, contour
enhancement and object identification were performed. The digital
image processing was done using the following routines: (1)
digital contrast enhancement, (2) low-pass filtering, (3) shade defi-
nition and correction (i.e. background subtraction), (4) scraping
(i.e. remove non-cellular objects defined by pixel size), (5) inter-
active thresholding, (6) dilating and eroding objects (i.e. closing
cell outline), (7) manual editing ofcell outline, ifneeded (i.e. only
in case ofcontour defects that need to be closed), (8) filling object,
(9) inverting image, (10) measuring object. These steps are auto-
matic except for the interactive thresholding and editing, which
may require supervision. The image processing was done from a
rerun of stored images; a routine experiment base on 40 images of
one cell takes about 10 min to measure. The video image had 768
x 512 pixels and the cell represented about 10 000 pixels in size,
corresponding to about 2.5% of the entire video frame. The LCD
video camera had approximately the same spatial resolution. Phase
contrast microscopy was used, which helps to identify the cells in
that the diffraction is easily traced by the image thresholding. The
microscope focusing was done by a strict routine guided by the
cell phase shift; this was to secure a reproducible image ofthe cell.
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Figure 2 Dose-response curves for effects of EMP on PCA in human
malignant glioma cells. Glioma cells were harvested and introduced into a
perifusion chamber and the geometry of an individual cell was monitored by
computerized image processing. After 10 min the medium was abruptly
changed to perifusion with EMP (0, 20, and 40 mg 1-', A, B, C) for 30 min.
Mean values ± s.e.m, n = 6, 7 and 22 for the different concentrations
respectively
The cell geometry was determined in terms of projected cell
area (PCA) and perimeter shape factor (PSF). The PCA was the
two-dimensional area of the cell, whereas PSF was calculated by
the computer from the PCA and the perimeter;
Perimeter shape factor = 4t PCA/(perimeter)2 (1)
The PSF represents the roundness ofthe cell, with a value of 1.0
representing a perfect circular shape. For geometric comparison,
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Figure 3 Effects of ouabain on PCA and interactive effects of ouabain on the
EMP-induced cell geometry change. Glioma cells were harvested and
introduced into a perifusion chamber and the geometry of an individual cell
was monitored by computerized image processing. After 10 min the medium
was abruptly changed to either (A) ouabain (100 ,umol 1-') or (B) ouabain
(100 lmol 1-1) plus EMP (40 mg 1-') within the same test-perifusion medium
for 30 min perifusion. The interactiqn of ouabain on the EMP response was
analysed by calculating the PCA differential curve (C). This was done by
subtracting the ouabain-alone curve from the ouabain/EMP curve to yield the
differential response to EMP. Mean values ± s.e.m. n = 5 + 5 cells
the PCA was recalculated into both diameter and cell volume of an
assumed spherical cell shape. The mean PCA of all cells of the
first 10-min perifusion with basal medium alone was used as base-
line control and set to 100%.
In order to evaluate the specific effects of EMP when tested in
combination with an ion-channel blocker, a differential curve was
calculated. This was done by subtracting the curve for EMP plus
Time (min)
Figure 4 Effects of bumetanide on PCA and interactive effects of ouabain on
the EMP-induced cell geometry change. Glioma cells were harvested and
introduced into a perifusion chamber and the geometry of an individual cell
was monitored by computerized image processing. After 10 min the medium
was abruptly changed to either (A) bumetanide (10 gmol 1-') or (B)
bumetanide (10 imol 1-') plus EMP (40 mg l-1) within the same test perifusion
medium for 30 min perifusion. The interaction of bumetanide on the EMP
response was analysed by calculating the PCA differential curve (C). This
was done by subtracting the ouabain-alone curve from the ouabain/EMP
curve to yield the differential response to EMP. Mean values s.e.m.
n = 5 + 5 cells
ion-channel blocker from that of ion-channel blocker alone.
However, to reduce the effects of noise in the subtraction, the
curve for ion-channel blocker alone was smoothed by a floating
average calculation; this was the average of three recordings
flushed along the time axis.
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Experimental operation of perifusion
A small volume of cell suspension, about 50 ,tl, was injected into
the slit entrance of the cell compartment and the cells were
allowed to settle for 1 min before the perifusion was started with
basal medium (Eagle's MEM without fetal calfserum). Within this
minute the cells stick to the perifusion compartment bottom and no
motion ofthe cell is noticed during perifusion. A cell was selected
at random and perifused for 10 min, after which time the pumping
was stopped. The basal medium in the reservoir was then replaced
by a test medium and the perifusion continued for another 30 min.
During medium replacement, and with the pump stopped, the cell
remained in basal medium to be exposed to the test medium only
after the pump was restarted. This exposure becomes very distinct
because of the sharp medium interface between basal and test
medium that enters the cell compartment (Engstrom and
Savendahl, 1995).
Chemicals
Eagle's MEM was from Life Technologies, Paisley, UK, and fetal
calf serum from Biochrom, Berlin, Germany. Furosemide was
a gift from Svenska Hoechst, Stockholm, Sweden. Ouabain and
bumetanide were obtained from SigmaChemical Company, StLouis,
Missouri, USA. 86RbCl was fromAmersham, Buckinghamshire, UK,
and micronized estramustine from Pharmacia, Uppsala, Sweden. All
other chemicals were ofanalytical grade.
Statistics
Results are given as mean values and standard errors (s.e.m.). For
the evaluation of microperifusion data, a linear regression was
calculated for each individual cell during testperifusion, 11-40 min,
and extrapolated to 10 min (0 min oftest perifusion). Dose-response
curves were based on mean values between 5 and 22 min. The mean
values for linear slopes and intercepts and the dose-response corre-
lations were compared by using an unpaired Student's t-test with
correction for unequal variance and numbers between groups.
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RESULTS
Geometry of perifused glioma cells
The glioma cells were selected atrandom regardless of any assumed
interface of the cell mitotic cycle. The intercell variation in geom-
etry of the glioma cells was relatively constant with the measured
PCA and shape factors indicated in Table 1. In Table 1 the PCA was
also recalculated for each cell to an assumed spherical cell volume.
Geometric dose-response effects of EMP
When glioma cells were perifused at basal conditions the PCA
decreased with time, with an end PCA of 96.6 2.2% of basal;
however, this did not become significant (n = 6, Figure 2A).
Neither was the PCA slope calculated from medium change to the
end of the perifusion significant: -0.13 ± 0.07% s-' (P < 0.20).
Note also that the medium exchange procedure, basal to basal
medium, did not affect the cell geometry (Figure 2A). When the
cells were exposed to EMP the PCA showed a rapid increase; at
4 min EMP perifusion the PCA was 103.1 ± 2.7% at 20 mg 1-'
EMP (NS, n = 7) and 106.2 ± 1.3% at 40 mg 1-' EMP (P < 0.001,
n = 22) (Figure 2B and C). These acute changes in PCA also
90
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30 40
Figure 5 Effects of furosemide on PCA and interactive effects of ouabain on
the EMP-induced cell geometry change. Glioma cells were harvested and
introduced into a perifusion chamber and the geometry of an individual cell
was monitored by computerized image processing. After 10 min the medium
was abruptly changed to either (A) furosemide (100 gmol 1-'), or (B)
furosemide (100 ,umol 1-1) plus EMP (40 mg 1-1) within the same test
perifusion medium for 30 min perifusion. The interaction of furosemide on the
EMP response was analysed by calculating the PCA differential curve (C).
This was done by subtracting the ouabain-alone curve from the ouabain/EMP
curve to yield the differential response to EMP. Mean values ± s.e.m.
n=5+5 cells
produced positive slopes that were significant at 40 mg 1-' EMP,
1.77 ± 0.32% s-' (10-14 min, P < 0.001). During the remaining
perifusion the PCA increased further with time, with a significant
positive slope for 20 mg 1-1 EMP, 0.18 ± 0.06% -Is (14-40 min,
P < 0.05), whereas for 40 mg 1-1 EMP the slope was only 0.10 +
0.08% s-'(NS) as it seemed to have reached a maximum by the
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beginning of EMP perifusion. The PCA at the end of the 30-min
EMP perifusion reached 108.9 ± 3.5% and 107.9 ± 2.2% for
20 mg 1-' and 40 mg 1-l EMP respectively, without any difference
between the two concentrations of EMP (Figure 2B and C).
Effects of ouabain on the EMP-induced geometry
change
In Figure 3, the effects of ouabain (100gmol 1-') are shown. When
the cells were exposed to ouabain alone, the PCA increased
rapidly, with a peak of 106.9 ± 2.9% at 13 min of ouabain perifu-
sion (P < 0.05, Figure 3A). When ouabain was added to the EMP
perifusion (40 mgl-l EMP + 100,umol 1-1 ouabain), the acute
response, seen for ouabain and EMP alone, was eliminated (Figure
3B); after 3 min perifusion the PCA was only 99.2 ± 2.2%. Note
that EMP at 40 mg 1-1 was shown to produce an instant increase in
PCA (see Figure 2C). When the curve for ouabain alone (see
Figure 3A) was subtracted from the curve of combined ouabain
and EMP perifusion (Figure 3B), the resulting curve (Figure 3C)
suggested that the effects of EMP were abolished by this ion-
channel blocker with regard to PCA.
Effects of bumetanide and furosemide on the
EMP-induced geometry change
In Figure 4, the effects of bumetanide (10 gmol 1-1) are shown and
indicate an immediate decrease in PCA to 97.0 ± 1.2% (P approx-
imately 0.05, n = 6) at 11 min ofbumetanide perifusion. However,
the second recording, at 12 min along the time axis, indicates a
dramatic increase in PCA to 104.7 ± 3.6% (P approximately 0.05).
After this response, the PCA approached the baseline for the
remaining perifusion period (Figure 4A). When bumetanide was
added to EMP (40 mg 1-1), the acute response seen for EMP alone
appeared unchanged during the first minute of perifusion (Figure
4B, see PCA at 12 min). In contrast to the curve with EMP alone,
however, the PCA then rapidly approached the baseline during a
4-min period and the EMP effect (Figure 2C) was completely
abolished. This is demonstrated by a background subtraction,
in which the bumetanide curve was subtracted from the
bumetanide/EMP curve (Figure 4C).
In Figure 5 furosemide (100 ,umol 1-1) is shown to exhibit
substantial effects on the PCA of glioma cells; the PCA increased
rapidly to a maximum of 107.6 ± 1.6% (P <0.001, n = 5) at 14 min
offurosemide perifusion (Figure SA) but then completely returned
to the baseline with a negative slope value of -0.79 ± 0.16% s-I
(P < 0.001) during the 14-24 min furosemide perifusion period.
When furosemide (100 gmol 1-1) was added to the EMP
(40 mg 1-1), the acute response seen for EMP alone seemed to
be retarded in its increase, with a maximum at 13 min perifusion
of 105.4 ± 1.8% (P < 0.05, n = 5, Figure SB). This was of about
the same magnitude as the acute response for EMP; however,
note also that the PCA change clearly mimicked that for
furosemide alone (Figure 2C). During the chosen time period of
14-24 min test perifusion, the significant slope observed for
furosemide alone disappeared (Figure SA). In addition, by the
end of the 30-min test perifusion the PCA was 107.1 ± 2.0%
(P < 0.05), and thus almost identical to the results for EMP alone
(107.9 ± 2.2%). This is further strengthened by subtracting the
curve for furosemide alone from the EMP-furosemide response
(Figure SB) (Figure 5A) with a resulting curve that shows a long-
term EMP effect, whereas the acute EMP response was completely
abolished (Figure SC).
DISCUSSION
In this study we show that the size of cultured glioma cells varies
constantly during the cytotoxic action of EMP. Because of the
rapid dynamics of these changes, we have focused on the possible
role of ion channels in these volume-regulating mechanisms. This
study was done with the use of a new computerized microscopic
technique, which provides the ability to follow early alterations in
cell size and shape of cells perifused with anticancer drugs.
EMP is a complex between oestradiol-17P and the alkylating
agent nor-nitrogen mustard, and is widely used in the treatment of
advanced prostatic cancer (Jonsson et al, 1977; Madajewics et al,
1980). We have recently shown that EMP is specifically metabo-
lized by glioma cell in vitro (von Schoultz et al, 1990) and in vivo
in rats (Bergenheim et al, 1993) and humans (Bergenheim et al,
1994). EMP and its main metabolite have demonstrated a marked
cytotoxic effect on the cultured human malignant glioma cell line
(MG-25 1) (von Schoultz et al, 1988), the cell line used in this
study. The mechanisms of the cytotoxic action of EMP are still not
completely understood. Earlier studies have suggested micro-
tubules as the main target for the cytotoxic effects of EMP
(Hartley-Asp, 1984; Wallin et al, 1985; Bjermer et al, 1988).
Although EMP contains a highly active alkylating agent, it has
been claimed that its cytotoxic effect is mediated through non-
DNA targets (Tew et al, 1983). However, it has also been demon-
strated that EMP cytotoxicity may involve a direct interaction with
DNA and/or cell membrane components (Henriksson et al, 1990;
von Schoultz et al, 1991). We have also shown that estramustine
induces early DNA fragmentation, suggestive of an apoptotic cell
death, in tumour tissue but not in brain tissue from the same
animals (Vallbo et al, 1995). Moreover, EMP affects microtubule
integrity and displays cytotoxic action in glioma cells but not in
astrocytes (Yoshida et al, 1994). It is possible that the cell death
induced by EMP may primarily be a membrane/cytoskeleton-
triggered apoptotic cell death rather than a direct chemical
interaction with the DNA.
Evidence that EMP cytotoxicity also involves a direct cell
membrane damage was suggested in a previous study by (1)
rubidium (86Rb) accumulation assay, (2) scanning electron
microscopy and (3) a new light microscopic technique of cell
microperifusion (Engstrom et al, 1991). In addition, 86Rb leakage
was found to be a very early event following EMP exposure (86Rb
is a commonly used tracer for potassium ion flux). In earlier
studies, we had observed effects on 86Rb fluxes following long-
term EMP treatment in glioma cells (von Schoultz et al, 1991) and
in transformed fibroblasts (Henriksson et al, 1990). Membrane
damage might be related to previous observations that EMP, like
other substances such as diamide and tert-butylhydroperoxide, is
capable of generating free oxygen radicals. The direct involve-
ment of free oxygen radicals in EMP toxicity has been shown in
both a cell-free system (Grankvist et al, 1988) and in studies on
different cell cultures (Henriksson et al, 1990).
Glioma cells demonstrate a consistent morphological alteration
when exposed to EMP, starting at a concentration of 20 mg 1-1.
EMP caused an obvious dose-response pattern in terms of
increase in cell size without corresponding changes in shape
factor. The cytotoxicity induced by EMP could be due to its micro-
tubule depolymerization properties. This could be caused by inter-
action with tubulin and/or with microtubule-associated proteins
(MPAs). Previous investigations have shown that high concentra-
tions of EMP can inhibit microtubule polymerization in vitro by
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binding to MPAs. With this new computerized system no
membrane blebs were detected as was the case in our previous
report (Engstrom et al, 1991). This could be because ofthe differ-
ence in microscopy; phase contrast was used here rather than
previous bright-field illumination and, further, the contour tracing
was done interactively and not digitally (Engstrom et al, 1991).
This discrepancy could also explain the lack of changes in shape
factor observed with the previous technique.
The EMP-induced increase in cell volume indicates a membrane
leakage, also shown by a decreased t6Rb influx with a net flow of
ions and water into the cell (Engstrom et al, 1990). This ion and
water leakage may either be of non-specific nature or occur by
different ion channels (Hoffman and Simonsen, 1989). Perifusion
ofthe glioma cells with ion-channel blockers ouabain, bumetanide
or furosemide concomitant with EMP appeared to block the
increase in cell volume induced by EMP. The actin cytoskeleton
may be involved in detection ofcell volume and/or transduction of
a volume signal to volume-sensitive ion membrane transporters
(Haas, 1994). It is thus possible that blockage of Na+, K+-ATPase
and/or Na+, K+, Cl- co-transport activation by EMP could prevent
morphological changes, DNA fragmentation and cytotoxicity of
the drug. At least three different potassium flux pathways seem to
exist in the tumour cell line used (malignant glioma U251 MG) i.e.
Na+, K+-ATPase, Na+, K+, Cl- co-transport system and K channels
with high conductance. The glioma cell line only displays
moderate Na+, K+, Cl- co-transport activity, so it is perhaps not
surprising that we did not find any reduction ofthe cytotoxic effect
of EMP with furosemide and bumetanide in this cell line
(Sandstrom et al, 1994).
In conclusion, this study shows that inhibitors of anion trans-
membrane transport completely block the EMP-induced cell
volume increase. The interrelation between plasma membrane ion
transport and cell volume changes by EMP, and the possible
linkage to microtubule modulation and apoptosis-related DNA
fragmentation are interesting observations that may help in solving
the mechanisms of EMP cytotoxicity. The microperifusion tech-
nique for detecting and evaluating rapid cell volume changes in
vitro could also serve as a valuable tool in predicting cytotoxicity
during chemotherapy in clinical practice.
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